Ignite Creation Date:
2025-12-24 @ 7:08 PM
Ignite Modification Date:
2025-12-27 @ 12:08 PM
Study NCT ID:
NCT02355457
Status:
RECRUITING
Last Update Posted:
2024-05-13
First Post:
2015-01-30
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Biomarkers in Acute Cardiac Care
Sponsor:
Universitätsklinikum Hamburg-Eppendorf
Organization:
Study Overview
Official Title:
Biomarkers in Acute Cardiac Care
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BACC
Brief Summary:
The primary aim of the study is to investigate new cardiac biomarkers and algorithms to diagnose acute coronary syndrome in patients with suspected acute myocardial infarction.
Detailed Description:
The primary aim of the study is to detect and evaluate new cardiac biomarkers, evaluate and improve acute coronary syndrome (ACS) risk scores, which takes into account clinical, gender specific, psycho-social and lifestyle-risk factors, protein patterns and genetic variability in addition to the classical risk factors with respect to the primary endpoint of acute myocardial infarction.
Secondary study aims are :
* To provide estimates for the incidence of ACS in patients presenting with recent onset chest pain;
* To provide accurate, quantifiable measures of precursors of ACS;
* DNA, RNA, cells, and serum/plasma for comprehensive genetic, gene expression and proteomic studies
* To explore the impact of ACS candidate genes on cardiovascular risk stratification by using genome-wide analyses and a biological systems approach;
* To explore proteins relevant for ACS;
* To allow the identification of new therapeutic targets;
* To evaluate the impact of socio-economic factors on ACS and CAD risk.
Patients will be followed up during the hospital stay. Afterwards a telephone follow-up will take place after 30 days, 6, 24 and 48 months.
Secondary study aims are :
* To provide estimates for the incidence of ACS in patients presenting with recent onset chest pain;
* To provide accurate, quantifiable measures of precursors of ACS;
* DNA, RNA, cells, and serum/plasma for comprehensive genetic, gene expression and proteomic studies
* To explore the impact of ACS candidate genes on cardiovascular risk stratification by using genome-wide analyses and a biological systems approach;
* To explore proteins relevant for ACS;
* To allow the identification of new therapeutic targets;
* To evaluate the impact of socio-economic factors on ACS and CAD risk.
Patients will be followed up during the hospital stay. Afterwards a telephone follow-up will take place after 30 days, 6, 24 and 48 months.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: